Prevest Denpro Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Growth decelerated but profitable: FY26 revenue grew 13.9% but Q4 slowed to just 2.63% on geopolitical disruption; even so, Q4 PAT rose 13.23% and EBITDA margin hit 40.87% as operational efficiency offset the top-line drag.
• International engine is two-speed: U.S. business surged 37.58% while the new Dubai subsidiary sat idle all quarter because the Middle East conflict erupted the month after it opened.
• Digital dentistry is the long bet: Management expects 40% of dental-office procedures to have a digital workflow within five years; 3D printer sales jumped ~162% and an indigenous printer is targeted for 2028.
• Margins held despite the squeeze: Full-year margins moderated only marginally from the prior year, with disciplined cost management absorbing inflation, tariff friction and supply-chain disruption.
• What to watch next quarter: Whether Dubai online sales actually begin, whether Oradox recovers its 2% decline, and whether the four near-market products (caries removal agents, endodontic irrigants, self-etching resins, periodontal gels) receive launch timelines.

Top-Line Trajectory

• Full-year growth, Q4 stall: FY26 revenue grew 13.9% on balanced domestic (9%) and export (17.58%) contributions, but Q4 growth collapsed to 2.63% as geopolitical tensions, war-related developments and global shipping disruption fractured customer ordering patterns and export dispatches.
• H2 rescued the year: Second-half sales rose 12.06% vs H2 FY25, and domestic H2 sales jumped 16.19% vs H1 FY26, reflecting improving market traction and the effectiveness of the commercial strategy after a weak first half.
• Growth moderation is structural, not just cyclical: Management acknowledged growth has come down from earlier years because the company is in a later stage; geopolitical challenges in international markets have slowed fast growth, but 17–18% growth this year is still positive given the environment.
• Domestic recovery levers: Expansion of the distribution network into Tier 2 and Tier 3 cities, a strengthened sales team, and a wider product portfolio (disinfectants, Rotoflex) drove the H2 rebound after H1 was disrupted by GST changes, weather events including floods in Jammu, and major events.

Sai Kalyan: "we expect in the next 5 years, at least 40% of all procedures, which are done at the dental office will be having a digital workflow. So, we are working with our enormous speed in this area."

International Footprint

• U.S. is the standout: U.S. business grew 37.58% YoY, driven by Axiodent online sales, direct sales from India, and private-label business from large companies that approached Prevest at U.S. exhibitions.
• Dubai subsidiary stalled at launch: The wholly owned UAE subsidiary was established in February; the Middle East crisis erupted in March, delaying commercial operations entirely. Two sales managers are employed and working, product registration in Dubai is nearly complete, and online sales are expected to start next month.
• Oradox hit by regulatory and geopolitical friction: Oradox sales fell 2% because U.S. exports were affected by the new MoCRA portal requirements, and a planned large consignment to Dubai after the Dubai exhibition did not materialize due to the war situation. Products are now registered with MoCRA in the U.S. and with Dubai Municipality for cosmetics.
• OEM pipeline building: Prevest currently does OEM for 3–4 big companies and expects to add another couple of large OEM partners in the next two years.

Namrata Modi: "While the commencement of commercial operations was delayed due to geopolitical tensions and conflict in the Middle East, which impacted overall business activity, the underlying market opportunity remains strong."

Profitability & Cost Management

• Q4 margin expansion despite weak revenue: EBITDA margin improved to 40.87%, PBT margin to 38.38%, and PAT margin to 28.61% in Q4, with PAT growing 13.23% even as revenue grew only 2.63%.
• Full-year margin held firm: Margins moderated only marginally compared with the previous year and remained among the strong, reflecting disciplined cost management and operational efficiency.
• Cost levers deployed: Continuous improvement in manufacturing processes, higher capacity utilization, supply chain optimization and disciplined cost management mitigated inflationary pressures while maintaining healthy profitability.
• Capacity headroom exists: A new production line is very likely to increase capacity utilization in the coming years, offering further operating leverage.

Product Pipeline & Digital Dentistry

• Four near-market products: Test licenses have been completed for caries removal agents, endodontic irrigants, self-etching resins and periodontal gels; all are at TRL 7 (Technology Readiness Level 7), described as almost market ready.
• 3D printing gaining traction: Printer sales under the Omni brand (launched November) are up ~162% and resin sales up ~40.5%. An indigenous 3D printer is in active development with a target of 2028.
• Rotoflex building repeat demand: The endodontic file system is receiving encouraging response from dental professionals with increasing repeat demand validating its clinical performance.
• Disinfectant business commercialized: Commercialization began during FY26 with highly encouraging initial customer response; management sees significant long-term growth potential and will continue investing in a disciplined, phased manner.
• Import substitution adds revenue: The company is developing in-house raw materials previously imported from other countries, generating revenue through import substitution while reducing supply-chain dependency.

Competitive Position & Go-to-Market

• Price and quality moat vs MNCs: Competitors include Ivoclar, Dentsply and 3Shape. Management argues low Indian production costs and high import duties mean competitors can never beat Prevest on price, while quality management certificates prove parity on quality.
• Educational engagement as a demand driver: Approximately 16 structured training programs were conducted for dental professionals, clinics and institutions across the year, deepening clinician relationships and supporting new product adoption.
• Exhibition-led U.S. growth: Aggressive exhibition participation is driving U.S. business, with management very positive and hopeful it will grow more in the next few years.
• Oradox recovery plan: Management expects 2–3 new product launches and aims to compensate for the 2% sales decline this year.

Sai Kalyan: "The cost of production in India is so low and the import duties are so high, they can never beat us on price. And the quality surely since we have good quality management certificates that proves the quality."

Guidance & Commitments

Key Metrics